Letters

Adjuvant treatment with tamoxifen

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7037.1036 (Published 20 April 1996) Cite this as: BMJ 1996;312:1036

Side effects may have been overstated

  1. Michael Baum,
  2. Jack Cuzick
  1. Chairman, breast cancer trials coordinating committee, UK Coordinating Committee on Cancer Research Chairman, international breast cancer intervention study working party International Breast Cancer Intervention Study Coordinating Centre, PO Box 123, London WC2A 3PX

    EDITOR,—Use of clinical announcements by the National Cancer Institute to influence policy on the European side of the Atlantic1 is a dubious and previously discredited process, and this would not be the first time that such an announcement has caused distress on this side of the Atlantic. The data cited in these “alerts” are unpublished and not subjected to peer review and (from what we can glean from the limited amount of information available) are based on so few events …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe